AGEN — AGENUS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1098972 ·
Last close
$7.67
Market Cap
$345.22M
52W High
$8.85
52W Low
$2.85
ADV30
2,113,740
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 34,518,000 | 19,759,000 | 11,293,000 | -550,000 | 172,692,000 | 18,738,000 | 378,542,000 |
| Mar 2026 | 33,736,000 | 21,914,000 | 15,054,000 | 39,226,000 | 186,456,000 | 34,996,000 | 414,439,000 |
| Dec 2025 | 34,204,000 | 26,693,000 | 14,398,000 | -10,578,000 | 226,798,000 | 2,998,000 | 504,659,000 |
| Sep 2025 | 30,235,000 | 5,997,000 | -4,863,000 | 63,914,000 | 233,891,000 | 3,458,000 | 514,759,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,527,000
Investing CF
$70,089,000
Financing CF
$32,006,000
CapEx
$-79,000
Dividends Paid
—
Buybacks
$-92,000
EPS Diluted TTM
$0.93
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,143,539,000
Inventory
—
Receivables
$14,062,000
ST Investments
—
EBIT TTM
$119,640,000
Pretax Income TTM
$62,493,000
Interest Exp TTM
$57,147,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$132,693,000
EBITDA
$40,610,000
Free Cash Flow
$-74,785,872
Enterprise Value
$379,410,080
Total Cash
$18,738,000
Total Debt
$40,708,000
Shares Out
45,009,670
Trailing EPS
$2.99
Book Value
$-4.67
ROE
—
ROA
12.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 114,196,000 | -20,556,000 | 115,000 | 226,798,000 | 504,659,000 | — | -77,195,000 |
| Dec 2024 | 103,463,000 | -124,429,000 | -227,212,000 | 226,271,000 | 532,695,000 | — | -158,315,000 |
| Dec 2023 | 156,314,000 | -160,105,000 | -245,761,000 | 313,913,000 | 462,295,000 | — | -224,202,000 |
| Dec 2022 | 98,024,000 | -180,242,000 | -220,074,000 | 413,556,000 | 468,458,000 | — | -175,373,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.06
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $8.00 · spot: $7.67 · call volume: 114 · put volume: 92
Expected Move to 2026-09-18:
±$1.66
(21.64%) —
implied range
$6.01 –
$9.33
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | $348.84M | $2.50 | — |
| PALI | PALISADE BIO, INC. | $350.28M | $2.01 | — |
| STRO | SUTRO BIOPHARMA, INC. | $339.75M | $20.49 | — |
| PROK | PROKIDNEY CORP. | $336.37M | $1.61 | — |
| SABS | SAB Biotherapeutics, Inc. | $329.37M | $3.62 | — |
News headlines (Yahoo Finance, 1h cache)
Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions
2026-08-16 13:07 · Yahoo
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
2026-08-07 21:45 · Yahoo
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing
2026-07-17 20:11 · Yahoo
Agenus stock doubles as biotech narrows Phase 3 bet
2026-07-14 14:17 · Yahoo
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?
2026-07-14 10:15 · Yahoo
AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment
2026-07-13 18:25 · Yahoo
Agenus shares surge as company secures up to $340M to advance colon cancer trial
2026-07-13 16:53 · Yahoo
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
2026-07-13 14:02 · Yahoo
Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)
2026-07-13 12:25 · Yahoo
Agenus surges on study pivot; Apnimed lines up an IPO
2026-07-13 11:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.